Lilly’s donanemab shows encouraging results in Phase 3 Alzheimer’s trial

Lilly’s donanemab shows encouraging results in Phase 3 Alzheimer’s trial

Eli Lilly and Company (Lilly) revealed complete results from its Phase 3 TRAILBLAZER-ALZ 2 study at the 2023 Alzheimer’s Association International Conference (AAIC), indicating that the experimental drug, donanemab, significantly slowed the cognitive and functional decline in patients with early symptomatic Alzheimer’s disease. The data was simultaneously published in the Journal of the American Medical […]

Lilly bags Retevmo FDA approval for RET-driven lung and thyroid cancers

Lilly bags Retevmo FDA approval for RET-driven lung and thyroid cancers

Retevmo FDA approval : Eli Lilly and Company (Lilly) has secured approval from the US Food and Drug Administration (FDA) for Retevmo (selpercatinib, 40mg and 80mg capsules) for the treatment of adults with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC). Retevmo has also been approved by the FDA for the treatment […]

Lilly launches LIBRETTO-431 clinical trial for selpercatinib in NSCLC

Lilly launches LIBRETTO-431 clinical trial for selpercatinib in NSCLC

Eli Lilly and Company (Lilly) has initiated the phase 3 LIBRETTO-431 clinical trial to evaluate selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) in patients who are treatment-naïve. The US pharma company is aiming to enroll 400 patients in the late-stage clinical trial. The patients will be grouped randomly to be subjected to […]

Eli Lilly completes $8bn acquisition of Loxo Oncology to expand oncology portfolio

Eli Lilly completes $8bn acquisition of Loxo Oncology to expand oncology portfolio

Eli Lilly and Company, the US-based pharmaceutical giant, has finalised its $8 billion acquisition of Connecticut-based biopharmaceutical firm Loxo Oncology, a move expected to significantly enhance its oncology portfolio. The deal, initially announced in January 2019, marks a pivotal step in Lilly’s strategy to focus on precision medicines tailored for cancers driven by specific gene […]